ENA0000GenomicsMount SinaiSchool of Medicinehttps://www.ebi.ac.uk/ena/browser/view/PRJNA144339Homo sapiensTo understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3+ T cells, neutrophils, CD11c+ and CD83+ myeloid DCs, but no increase in CD1c+ resident myeloid DCs. In relapsed lesions, there were many CD11c+CD1c-, inflammatory myeloid DCs identified by TNFSF10/TRAIL, TNF, and iNOS. CD11c+ cells in relapsed lesions co-expressed CD14 and CD16 in situ. Efalizumab induced an improvement in many psoriasis genes, and during relapse, the majority of these genes reversed back to a lesional state. Gene Set Enrichment Analysis (GSEA) of the transcriptome of relapsed tissue showed that many of the gene sets known to be present in psoriasis were also highly enriched in relapse. Hence, on ceasing efalizumab, T cells and myeloid cells rapidly enter the skin to cause classic psoriasis. Overall design: To determine the transcsriptome of skin samples in 4 responding patients who relapsed after receiving efalizumab for treatment of psoriasis, using paired baseline non-lesional (=NL, n=2); lesional (LS, n=4);week 12 post-treatment (week 12, n=4), and relapse (n=4).ENAneutral lipid storage disease with ichthyosis, dTAF[[II]]230, TAF[[II]]250, d230, ichthyosiform erythroderma with leukocyte vacuolation, triglyceride storage disease with impaired long-chain fatty acid oxidation, Mthfd, CD11a, Psoriasis and similar disorders, TAF200, CDS, Pustular Psoriasis of Palms and Soles, l(3)84Ab, dTAFII250, BG:DS00004.13, Psoriases, TAFII-250, TAF250/230, EfW1, Cell, Other and unspecified pityriasis, LFA-1A, dTAF230, Ly-15, dmTAF[[II]]230, PUSTULAR PSORIASIS OF PALMS SOLES, Psoriasis and similar disorders (disorder), LFA-1, relapse, TAFII250, OTHER PSORIASIS, dmTAF1, Pustulosis of Palms and Soles, (p180), Leukocyte adhesion glycoprotein LFA-1 alpha chain, Taf230, p230, TAF[[II]]250/230, TFIID, Other psoriasis and similar disorders excluding psoriatic arthropathy, PSORIAS RELATED DIS NEC, Dorfman-Chanarin syndrome, neutral lipid storage disease with ichthyotic, Dcs, psoriasis, LFA1A, Other psoriasis and similar disorders (disorder), Ly-21, Other psoriasis and similar disorders, Psoriasis and similar disorders NOS, TAF250, PITYRIASIS NEC & NOS, PUSTULOSIS OF PALMS SOLES, Taf[[II]]250, Taf200, dTAF[[II]]250, TAF[[II]]230, TFIID TAF250, E430024A07Rik, cel, cell, Palmoplantaris Pustulosis, Pustulosis Palmaris et Plantaris, ichthyotic neutral Lipid storage disease, Taf1p, DCs, TAF[II]250, Leukocyte function-associated molecule 1 alpha chain, Chanarin-Dorfman syndrome, CG17603, TAF[[II]], Psoriasis and similar disorders NOS (disorder), dTAF250, Chanarin-Dorfman disease, neutral Lipid storage disease with ichthyosis, DmelCG17603, CD11 antigen-like family member A, Taf250, Dorfman Chanarin syndrome., SR3-5, CD11A, disorder of cornification 12 (neutral lipid storage type), Psoriasis and similar disorders (navigational concept), NLSDI, associated, TAF, TAF230, Cd11a, TAF1human being, human., man0.00.00.00.00.00falseHomo sapiensPost-therapeutic relapse of psoriasis associated with CD11a blockade is associated with T cells and inflammatory myeloid DCs2022-05-122014-02-11PRJNA144339GSE30768223480039606